50 related articles for article (PubMed ID: 19903794)
1. T-cell responses to cyclin B1 are not restricted to p53-overexpressing tumors.
von Bergwelt-Baildon MS; Shimabukuro-Vornhagen A; Klein-Gonzalez N; Kondo E
Clin Cancer Res; 2009 Nov; 15(22):7106; author reply 7106-7. PubMed ID: 19903794
[No Abstract] [Full Text] [Related]
2. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
Sørensen RB; Andersen RS; Svane IM; Engell-Noerregaard L; Hadrup SR; Balslev E; Andersen MH; thor Straten P
Clin Cancer Res; 2009 Mar; 15(5):1543-9. PubMed ID: 19223507
[TBL] [Abstract][Full Text] [Related]
3. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
Suzuki H; Graziano DF; McKolanis J; Finn OJ
Clin Cancer Res; 2005 Feb; 11(4):1521-6. PubMed ID: 15746055
[TBL] [Abstract][Full Text] [Related]
4. Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53.
Vikhanskaya F; Erba E; D'Incalci M; Broggini M
Exp Cell Res; 1996 Sep; 227(2):380-5. PubMed ID: 8831577
[TBL] [Abstract][Full Text] [Related]
5. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.
Innocente SA; Lee JM
FEBS Lett; 2005 Feb; 579(5):1001-7. PubMed ID: 15710382
[TBL] [Abstract][Full Text] [Related]
6. Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression.
Yin XY; Grove L; Datta NS; Katula K; Long MW; Prochownik EV
Cancer Res; 2001 Sep; 61(17):6487-93. PubMed ID: 11522645
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53.
Cui XS; Donehower LA
Oncogene; 2000 Dec; 19(52):5988-96. PubMed ID: 11146550
[TBL] [Abstract][Full Text] [Related]
8. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
9. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
[TBL] [Abstract][Full Text] [Related]
11. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.
Bai M; Vlachonikolis J; Agnantis NJ; Tsanou E; Dimou S; Nicolaides C; Stefanaki S; Pavlidis N; Kanavaros P
Mod Pathol; 2001 Nov; 14(11):1105-13. PubMed ID: 11706071
[TBL] [Abstract][Full Text] [Related]
12. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
13. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast.
Geradts J; Ingram CD
Mod Pathol; 2000 Sep; 13(9):945-53. PubMed ID: 11007034
[TBL] [Abstract][Full Text] [Related]
15. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
[TBL] [Abstract][Full Text] [Related]
16. [Expression of phosphoprotein P53 in pathology].
Casazza S
Pathologica; 1993; 85(1097):321-34. PubMed ID: 8233649
[No Abstract] [Full Text] [Related]
17. Relationship between p53 and p27 expression following HER2 signaling.
Casalini P; Iorio MV; Berno V; Bergamaschi A; Børresen Dale AL; Gasparini P; Orlandi R; Casati B; Tagliabue E; Ménard S
Breast; 2007 Dec; 16(6):597-605. PubMed ID: 17604627
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
19. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer.
Zheng H; Hu W; Deavers MT; Shen DY; Fu S; Li YF; Kavanagh JJ
Am J Obstet Gynecol; 2009 Oct; 201(4):367.e1-6. PubMed ID: 19608149
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors.
Landberg G; Ostlund H; Nielsen NH; Roos G; Emdin S; Burger AM; Seth A
Oncogene; 2001 Jun; 20(27):3497-505. PubMed ID: 11429696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
